Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory study on omalizumab in patients with painful bladder syndrome
2008-006559-27Phase 2Completed
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of omalizumab in Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS), sponsored by IRCCS San Matteo Foundation. Primary endpoint: Primary efficacy of omalizumab at 12 months. Started Mar 2009; status: completed.
02
Drugs
omalizumab
03
Conditions
Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS)
Beyond the preview
Go deeper on 2008-006559-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006559-27.